Moderna Announces Key 2020 Investor and Analyst Events
December 11 2019 - 8:00AM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, today announced its key 2020 investor and analyst event
schedule, including Manufacturing & Digital Day, Vaccines Day,
Science Day and R&D Day.
Manufacturing & Digital Day - March 4
Moderna will host its first annual Manufacturing & Digital
Day on March 4, 2020 at 12:00 p.m. ET at the Company’s Norwood, MA
facility. Management and Moderna’s digital partners will discuss
the Company’s agile manufacturing strategy and highly automated
digital enterprise technology to enable rapid, scalable and
sustainable late stage development and commercialization.
Management will also discuss the Company’s Corporate Social
Responsibility initiatives across 5 priorities: patients,
employees, communities in which the Company operates, the
environment, and corporate governance and ethics.
Vaccines Day - April 14
The Company will host its first annual Vaccines Day on April 14,
2020 at 8:00 a.m. ET in New York City. This event will focus on
Moderna’s broad vaccines development portfolio which includes
investigational vaccines to prevent debilitating infectious
diseases from being passed from mother to child during pregnancy as
well as for the prevention of serious respiratory diseases.
Management also plans to discuss its approach to future development
of investigational vaccines, its commitment to public health
collaborations with foundations and government agencies, and its
overall perspective on the significant global commercial
opportunity that vaccines provide the Company.
Science Day - June 2
The Company will host its annual Science Day on June 2, 2020 at
8:00 a.m. ET in New York City. This event will focus on the
Company’s newest advances from its commitment to basic and applied
sciences.
R&D Day - September 17
The Company will host its annual R&D Day at 8:00 a.m. ET on
September 17, 2020 in New York City. This event will include
presentations from management and key opinion leaders with a focus
on Moderna’s clinical development pipeline.
Additional details for each event will be made available later.
Live webcasts will be available under “Events & Presentations”
in the Investors section of the Moderna website at
https://investors.modernatx.com. A replay of each webcast will be
archived on Moderna’s website for 30 days following the
presentation.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a
new class of transformative medicines for patients. mRNA medicines
are designed to direct the body’s cells to produce intracellular,
membrane or secreted proteins that have a therapeutic or preventive
benefit with the potential to address a broad spectrum of diseases.
Moderna’s platform builds on continuous advances in basic and
applied mRNA science, delivery technology and manufacturing,
providing the Company the capability to pursue in parallel a robust
pipeline of new development candidates. Moderna is developing
therapeutics and vaccines for infectious diseases, immuno-oncology,
rare diseases and cardiovascular diseases, independently and with
strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca, Plc.
(NASDAQ: AZN) and Merck, Inc. (NASDAQ: MRK), as well as the Defense
Advanced Research Projects Agency (DARPA), an agency of the U.S.
Department of Defense and the Biomedical Advanced Research and
Development Authority (BARDA), a division of the Office of the
Assistant Secretary for Preparedness and Response (ASPR) within the
U.S. Department of Health and Human Services (HHS). Moderna has
been named a top biopharmaceutical employer by Science for the past
five years. To learn more, visit www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191211005159/en/
Media: Colleen Hussey Senior Manager, Corporate Communications
617-335-1374 Colleen.Hussey@modernatx.com
Investors: Lavina Talukdar Head of Investor Relations
617-209-5834 Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024